Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | KIT | P10721 | 14/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 8/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22854604 | 0.89 | CSF1R (0.68) | CSF1RKITABL1DDR1LCK | |
| SCHEMBL22833738 | 0.86 | CSF1R (0.61) | CSF1RKITABL1DDR1 | |
| SCHEMBL13765874 | 0.85 | CSF1R (0.76) | CSF1RKITABL1DDR1LCK | |
| SCHEMBL4063968 | 0.85 | CSF1R (0.62) | CSF1RKITABL1DDR1 | |
| SCHEMBL22833769 | 0.84 | CSF1R (0.68) | CSF1RKITABL1DDR1 | |
| SCHEMBL13765780 | 0.82 | CSF1R (0.71) | CSF1RKITABL1DDR1NPC1 | |
| SCHEMBL22854667 | 0.80 | CSF1R (0.63) | CSF1RKITABL1DDR1LCK | |
| SCHEMBL18274636 | 0.80 | ABL1 (0.68) | CSF1RKITABL1DDR1LCK | |
| SCHEMBL15363657 | 0.78 | ABL1 (0.52) | CSF1RKITABL1DDR1LCK | |
| SCHEMBL22833605 | 0.78 | CSF1R (0.60) | CSF1RKITABL1DDR1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665709-B1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RES CO LTD (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-9024021-B2 | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-05-05 | — | — | US | disclosed |
| EP-2665709-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | Sun Pharma Advanced Research Company Limited (IN) | 2013-11-27 | — | — | EP | disclosed |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| WO-2012098416-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | ABL1, LCK, JAK2 | CSF1R 1228/4885KIT 214/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.